Status:
COMPLETED
An Enhanced Adherence Support Programme for Highly Active Antiretroviral Therapy (HAART)
Lead Sponsor:
Centre for the AIDS Programme of Research in South Africa
Collaborating Sponsors:
Doris Duke Charitable Foundation
Conditions:
HIV Infections
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
In southern Africa, TB is the most common first AIDS-defining condition. Initiating Antiretroviral therapy (ART) in HIV positive TB patients will lead to the inclusion of the majority of HIV/AIDS pati...
Detailed Description
Enhanced Adherence Support (E-ASP) All patients will receive sessions one and two of the Standard ASP. Following randomization, the intervention (experimental) arm patients receive the E-ASP describe...
Eligibility Criteria
Inclusion
- Patients enrolled in the CAPRISA CAT programme and the CDC.
- Willing and able to provide written consent to take part in the study.
- \> 18 years of age (to give consent for participation)
- Eligible for initiation of HAART (currently CD4+ \<200)
Exclusion
- Unwillingness or inability to adhere to the study schedule
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
297 Patients enrolled
Trial Details
Trial ID
NCT00408642
Start Date
August 1 2007
End Date
March 1 2011
Last Update
February 1 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CAPRISA eThekwini Clinical Research Site
Durban, KwaZulu-Natal, South Africa, 4001